clairop

IBS Treatment Options: Diet, Medicines, Therapy

Every evidence-based IBS treatment option in one place: diet, fiber, over-the-counter, prescription classes by subtype, gut-brain therapy, and what to skip.

Clairop Team19 min read

Photo: Jason Briscoe / Unsplash

The short answer

IBS treatment usually starts with diet and lifestyle, then adds a limited low FODMAP trial, soluble fiber, over-the-counter options, gut-brain therapies such as CBT or hypnotherapy, or prescription drug classes chosen by subtype. Most options help a minority beyond placebo, so the realistic goal is meaningful relief, judged over weeks, with your doctor.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

IBS treatment is rarely one thing. Guidelines from the American College of Gastroenterology, the American Gastroenterological Association and the British Society of Gastroenterology describe a menu: diet and lifestyle first, then a limited low FODMAP trial, soluble fiber, over-the-counter products, gut-brain therapies, and prescription drug classes matched to your IBS subtype.

This page is the map. Each section is short and points to a deeper article. It describes what the evidence says about each option, not what you should take, because choosing and starting treatment belongs with your doctor or pharmacist.

What are the treatment options for IBS?

The options fall into five groups: diet and lifestyle, fiber, over-the-counter products, prescription drug classes, and gut-brain therapies. Guidelines do not rank one group as universally best. They suggest working through them in a sensible order, matching the choice to your subtype, your main symptom and your preferences (Lacy 2021, Vasant 2021).

Two points shape everything below. First, IBS is a disorder of gut-brain interaction, which is why treatments aimed at the gut and treatments aimed at the nervous system can both help. Second, the gains are often modest. In many trials the placebo group improved too, so the realistic aim is meaningful relief, not a symptom-free gut.

Before any of this, IBS should be diagnosed properly. Blood in the stool, unexplained weight loss, fever, symptoms that wake you at night, anemia, new symptoms after age 50, or a family history of bowel cancer or inflammatory bowel disease are reasons to see a doctor promptly, not to try treatments at home. The questions to ask a gastroenterologist about IBS article covers what to bring to that appointment.

Which IBS treatment options suit each subtype?

IBS treatment options differ by subtype (IBS-D, IBS-C and IBS-M), and this table lists what guidelines and trials discuss for each. It is a map of conversations to have, not a prescription list. Everything in the medicine rows is a decision for your doctor.

OptionIBS-DIBS-CIBS-MAll subtypes
Healthy eating, regular meals, trigger awarenessYesYesYesFirst-line
Limited low FODMAP trial with reintroductionYesYesYesDietitian-led
Soluble fiber (psyllium or ispaghula)SometimesOften discussedSometimesNot insoluble bran
Peppermint oil, antispasmodicsYesYesYesMainly pain and cramping
Low-dose tricyclic antidepressantsDiscussed in AGA IBS-D guidelineDiscussed in AGA IBS-C guidelineDoctor's judgmentGut-brain neuromodulator
Rifaximin, eluxadoline, alosetron, loperamideDiscussed in AGA IBS-D guidelineNot applicableDoctor's judgmentNone
Linaclotide, plecanatide, tenapanor, lubiprostone, tegaserod, polyethylene glycolNot applicableDiscussed in AGA IBS-C guidelineDoctor's judgmentNone
CBT and gut-directed hypnotherapyYesYesYesGut-brain therapy
ExerciseYesYesYesLimited evidence

Mixed-type IBS (IBS-M) has the least subtype-specific evidence. Few trials are designed around it, and treatment usually follows whichever symptom is bothering you most at the time. The difference between IBS-D and IBS-C article explains how the subtypes are defined.

What are the first-line IBS treatments?

First-line treatment is general healthy eating and lifestyle advice that any healthcare professional can give. The British Dietetic Association simplified its IBS dietary algorithm to first-line healthy eating and second-line low FODMAP advice from a dietitian (McKenzie 2016).

In practice, "traditional dietary advice" in a Swedish trial meant a regular meal pattern, avoiding large meals, and cutting down on fat, insoluble fiber, caffeine and gas-producing foods such as beans, cabbage and onions, with more emphasis on how and when to eat than on what (Bohn 2015). That is worth knowing because it was as effective as a low FODMAP diet in the same trial, and it is much less restrictive.

Lifestyle also includes movement. A systematic review of 14 randomized trials and 683 people found that exercise such as yoga, walking and tai chi had benefits for IBS, but the studies were at strong risk of bias, so no firm conclusion was possible (Zhou 2019). Gentle, regular movement is a reasonable thing to discuss, with realistic expectations.

For the practical side of managing a rough patch, see how to calm an IBS flare-up. People in r/ibs often describe a pattern of working through the obvious candidates, then discovering that the "IBS" label needed rechecking, a theme in threads such as PSA: your IBS-C may not be IBS-C and It was never IBS - it was BAM. Those are lived experiences, not medical evidence, but they are a fair reminder that if nothing helps, the diagnosis deserves a second look.

Is a low FODMAP diet worth trying?

A low FODMAP diet is worth discussing for many people, as a short structured process with reintroduction, ideally with a dietitian. The ACG recommends a limited trial of a low FODMAP diet to improve global IBS symptoms (Lacy 2021), and the BSG says it should be supervised by a trained dietitian with FODMAPs reintroduced according to tolerance (Vasant 2021).

The evidence is real but not overwhelming:

  • In a controlled crossover trial of 30 people with IBS, overall symptom scores averaged 22.8 mm on a low FODMAP diet against 44.9 mm on a typical Australian diet, on a 100 mm scale (Halmos 2014).
  • In a Swedish trial of 75 people, a low FODMAP diet reduced symptoms as well as traditional IBS dietary advice, with no clear advantage over it (Bohn 2015).
  • A meta-analysis of seven trials in 397 people found reduced global symptoms with low FODMAP against control diets (relative risk of symptoms remaining 0.69), while the gluten-free diet comparison was not statistically significant (Dionne 2018).

The diet has three phases: a short restriction, systematic reintroduction of each FODMAP group, then personalization, where you keep only what you need to limit. It is not meant to be permanent. See the low FODMAP food list for what is in which group and how long you should do the low FODMAP diet for the timeline.

Because restriction without a plan can leave people eating very narrowly, this is one place where a dietitian genuinely changes the outcome. Ask your doctor about a referral.

Does fiber help IBS, and which kind?

Soluble fiber helps some people with IBS, and insoluble fiber usually does not. A meta-analysis of 14 trials in 906 people found a benefit for fiber overall (relative risk of persisting symptoms 0.86, number needed to treat 10), but the benefit was seen only with soluble fiber (0.83, NNT 7), with no effect from bran (Moayyedi 2014).

A primary care trial of 275 people supports that picture. In the first month, 57% of the psyllium group reported adequate relief against 35% on placebo, while bran did no better than placebo overall, and the bran group had the most early dropouts, mostly because symptoms worsened (Bijkerk 2009). An earlier meta-analysis likewise found the fiber benefit was limited to ispaghula (Ford 2008).

The British Society of Gastroenterology states that soluble fiber is effective, that insoluble fiber such as wheat bran may worsen symptoms, and that soluble fiber should be introduced gradually to limit bloating (Vasant 2021). The detail on why some fiber helps and some hurts is in does fiber make IBS worse. Whether to try a fiber supplement, and which one, is worth checking with a pharmacist or doctor, particularly if you have other conditions or medicines.

Which over-the-counter options have evidence?

Three over-the-counter classes have trial evidence: soluble fiber, peppermint oil and antispasmodics. Probiotics are the unclear fourth. What is available without a prescription varies by country, so a pharmacist is the right person to ask what applies to you.

Peppermint oil. A 2019 meta-analysis of 12 trials in 835 people found peppermint oil improved global symptoms (risk ratio 2.39 in seven trials) and abdominal pain, with a number needed to treat of three for global symptoms (Alammar 2019). A later 8-week Dutch trial was less clear-cut: the pain-response endpoint did not differ significantly from placebo (46.8% and 41.3% against 34.4%), although some secondary outcomes improved with one formulation (Weerts 2020). In short, it has promise and mixed results. The peppermint oil for IBS article goes deeper.

Antispasmodics. In a pooled analysis, 22 trials with 1,778 people found antispasmodics beat placebo (relative risk of persistent symptoms 0.68), with otilonium and hyoscine showing the most consistent evidence (Ford 2008). They are aimed mainly at cramping and pain. Availability without prescription depends on the country and product.

Probiotics. A meta-analysis of 53 trials in 5,545 people concluded that particular strains or combinations may help global symptoms and pain, but it was not possible to draw definitive conclusions about which ones (Ford 2018). The ACG suggests against probiotics for global IBS symptoms (Lacy 2021). The upshot is that the category is unsettled; see probiotics for IBS for the strain-level detail.

Anti-diarrheal and laxative products. Loperamide has a conditional AGA recommendation for IBS-D on very low certainty evidence (Lembo 2022). For IBS-C, polyethylene glycol laxatives have a conditional recommendation on low certainty evidence (Chang 2022), and a 28-day trial showed more spontaneous bowel movements than placebo, but no improvement in abdominal pain compared with placebo (Chapman 2013). Bowel habit and abdominal pain are separate outcomes, and a product can help one without the other.

None of this is advice to buy or use any product. If you already use something, do not stop or change it based on this page.

Which prescription drug classes might your doctor discuss?

Doctors discuss prescription classes according to subtype and main symptom, usually after diet and first-line options. The AGA 2022 guidelines (IBS-D and IBS-C), the ACG 2021 guideline and the BSG 2021 guideline are the main sources. Everything here is "things your doctor may discuss", not a list to ask for by name, and drug choice depends on your history, other conditions and other medicines.

Neuromodulators and tricyclic antidepressants (across subtypes)

Low-dose tricyclic antidepressants are used in IBS as gut-brain neuromodulators, not because anyone thinks IBS is depression. A meta-analysis of 17 antidepressant trials found they improved IBS symptoms (relative risk of symptoms not improving 0.66) (Ford 2019). The AGA gives conditional recommendations for tricyclics in both IBS-D and IBS-C and conditionally recommends against SSRIs in both (Lembo 2022, Chang 2022).

The largest trial, ATLANTIS, enrolled 463 people in English general practices after first-line treatments had not been enough. IBS symptom severity at 6 months was 27 points better with low-dose amitriptyline than placebo on a 500-point scale, with 13% stopping because of side effects against 9% on placebo (Ford 2023). The BSG describes tricyclics as an effective second-line option that needs careful explanation (Vasant 2021).

Antispasmodics (across subtypes)

The AGA gives conditional recommendations for antispasmodics in both IBS-D and IBS-C on low certainty evidence. As above, the pooled trial evidence shows a benefit over placebo, concentrated on a few agents (Ford 2008).

Rifaximin (IBS-D)

Rifaximin is a gut-acting antibiotic studied in IBS without constipation. In the two TARGET trials, adequate relief of global symptoms in the first four weeks was about 41% against 31 to 32% on placebo (Pimentel 2011). A trial of repeat treatment in people who relapsed found 38.1% responders against 31.5% on placebo (Lembo 2016). A meta-analysis described it as having modest efficacy (Ford 2018). The ACG recommends rifaximin for global IBS-D symptoms (Lacy 2021) and the AGA gives a conditional recommendation (Lembo 2022).

Eluxadoline, alosetron and loperamide (IBS-D)

The AGA gives conditional recommendations for eluxadoline and alosetron (moderate certainty) and loperamide (very low certainty) in IBS-D (Lembo 2022). In two phase 3 trials of eluxadoline, about 24 to 30% of treated people met a composite pain and stool response over 12 weeks against roughly 16 to 17% on placebo. Pancreatitis occurred in 0.3% of treated people (Lembo 2016). Because each of these has specific cautions, the "who is this suitable for" question is exactly the kind a prescriber has to answer.

Ondansetron, a 5-HT3 antagonist used for nausea, has also been studied for IBS-D. A small trial missed its primary endpoint, though pooling suggested better stool consistency and fewer loose-stool days (Gunn 2023). It is research-stage for IBS, not a guideline staple.

For IBS-C, the AGA made a strong recommendation for linaclotide (high certainty) and conditional recommendations for tenapanor, plecanatide, tegaserod and lubiprostone (moderate certainty) (Chang 2022). The ACG similarly recommends chloride channel activators and guanylate cyclase activators for global IBS-C symptoms (Lacy 2021). In a 26-week trial of 804 people, 33.7% of linaclotide-treated people met the FDA pain and bowel movement response against 13.9% on placebo (Chey 2012).

Medicine side effects, interactions and eligibility matter here, so these conversations belong in a consultation. If you take a medicine already and are unsure about it, speak to your prescriber before changing anything.

How do gut-brain therapies help IBS?

Gut-brain therapies work on the signaling loop between gut and brain, which is why they can reduce gut symptoms. A network meta-analysis of psychological therapies found efficacy for self-administered or minimal-contact CBT (relative risk 0.61), face-to-face CBT (0.62) and gut-directed hypnotherapy (0.67), with CBT-based interventions and hypnotherapy most efficacious long term, although risk of bias was high and effects are probably overestimated (Black 2020). The ACG suggests gut-directed psychotherapy for global IBS symptoms (Lacy 2021).

CBT. IBS-specific CBT targets fear of symptoms, avoidance and gut-scanning habits. It has its own article: does CBT work for IBS.

Gut-directed hypnotherapy. In a 74-person trial, hypnotherapy, a low FODMAP diet and the two combined each gave at least a 20 mm improvement on a visual scale in about 71 to 72% of people, with no difference between groups (Peters 2016). See does gut-directed hypnotherapy work for IBS.

Apps. A trial of the CBT self-help app Zemedy found it improved symptoms more than an active control app, though only 74 of 136 people in the CBT arm gave data immediately after treatment (Hunt 2026). So apps are plausible, but with high dropout and less evidence than therapist-supported programs.

Vagus nerve work. Breathing and "vagus nerve" techniques are popular, but the evidence is thinner and mostly indirect. The vagus nerve and IBS article separates what is known from what is marketed.

Being referred for any of this does not mean your doctor thinks IBS is in your head. It reflects the evidence that the gut-brain axis is part of how IBS works.

What IBS treatments do not have good evidence?

Several widely promoted IBS treatments have weak, mixed or negative evidence, as listed here:

  • IgG food-intolerance tests. A 150-person trial found a 10% greater symptom reduction with an IgG-guided elimination diet than a sham diet, and the authors called it worthy of further research, not proven (Atkinson 2004). A single modest trial is not a basis for paying for a test or dropping many foods.
  • A blanket gluten-free diet. The pooled gluten-free diet result was not statistically significant (Dionne 2018), and the BSG does not recommend it for IBS (Vasant 2021). Celiac disease is a separate matter and should be tested before anyone removes gluten.
  • Fecal microbiota transplantation. A meta-analysis of five trials in 267 people found no overall benefit (relative risk 0.98), and oral capsules did worse than placebo in two pooled trials, while colonoscopic delivery looked better than autologous stool in two. The authors called for larger trials (Ianiro 2019).
  • Insoluble fiber. Wheat bran showed no benefit in meta-analysis (Moayyedi 2014).
  • Expensive supplement stacks. Most have no trial evidence for IBS at all. Absence of evidence does not mean harm, but it is a good reason to ask your doctor or pharmacist first.
  • GLP-1 weight-loss drugs. These are not IBS treatments, and they can change bowel habit. See Mounjaro and IBS for how people are reporting the interaction.

How do I know if an IBS treatment is working?

The honest answer is a record kept over weeks, compared against your starting point. IBS symptoms fluctuate by day, stress and the menstrual cycle, so one good or bad day tells you little. Trials judge over fixed periods: four weeks for the diet trials, eight weeks for peppermint oil, twelve weeks for psyllium, and six months for low-dose amitriptyline, according to the studies cited above (Bohn 2015, Weerts 2020, Bijkerk 2009, Ford 2023). Ask your doctor how long to judge each option you discuss.

Placebo arms matter here. In the peppermint trial, 34.4% of the placebo group met the pain-response endpoint. In the linaclotide trial, 13.9% of the placebo group met a stricter combined endpoint. A treatment can look as though it is working simply because symptoms vary. That is the case for tracking, and for changing only one thing at a time where your doctor agrees.

What to track:

  1. Pain and bloating on a simple daily scale.
  2. Stool form and frequency, using the Bristol chart, plus urgency, blood or mucus (blood is a reason to see a doctor promptly).
  3. Meals, so you can look back at what preceded a bad day.
  4. Medication and supplements, with the date you started or your prescriber changed something.
  5. A weekly score. The IBS Severity Scoring System, a validated 500-point scale, defines mild as 75 to 175, moderate as 175 to 300, severe above 300, and below 75 as remission range (Francis 1997).

Clairop, an iPhone app that is free to download and set up (using it needs a Clairop Pro subscription), logs meals by tap, voice, a typed sentence or a meal photo, one-tap Bristol entries with blood, mucus, urgency and night-time detail, symptoms and medication. Its trigger analysis only shows a food after at least 5 meals with and 5 without it, and tests three time windows, from under 6 hours to 1 to 3 days. It is not a medical device, not clinically validated and not diagnostic. See how it works and the method page for the exact limits.

When you see your doctor, a one-page summary of weeks of data beats memory. Clairop can produce a one-page GI visit report, labeled as patient-entered data, and you can export or delete your data with or without a subscription. That is a way to make the appointment more productive, not a substitute for it.

What should I ask my doctor about IBS treatment?

Good questions focus on sequencing and subtype. For example: which subtype do I fit, and what does that change? Which first-line steps have I not yet tried properly? Is a dietitian referral available for a low FODMAP trial? Which prescription classes would you discuss for my main symptom, and what are the side effects and interactions? Should the diagnosis be rechecked if I do not improve? Is there access to CBT or gut-directed hypnotherapy?

Written down, these questions make a short appointment go further. The full list is in questions to ask a gastroenterologist about IBS.

When should you see a doctor about IBS treatment?

IBS does not cause bleeding, unexplained weight loss, fever or anemia. See a doctor promptly if you have blood in your stool, unexplained weight loss, fever, symptoms that wake you at night, anemia, symptoms that start after age 50, or a family history of bowel cancer or inflammatory bowel disease. The ACG and BSG both frame IBS as a positive diagnosis after other conditions are considered, and suggest celiac testing and fecal calprotectin in people with diarrhea-type symptoms (Lacy 2021, Vasant 2021). If treatments are not helping, that is also a reason to go back, not to keep escalating on your own.

Common myths about IBS treatment

"There must be one right treatment." Trials show most options help a minority beyond placebo. Treatment is usually layered.

"A medicine means it is psychological." Neuromodulators and gut-brain therapies target the nerve signaling that carries IBS symptoms. They do not imply the symptoms are imagined.

"Natural means safe." Peppermint oil, fiber and supplements can still cause side effects or interact with medicines, so a pharmacist's check is worthwhile.

"If the first thing does not work, nothing will." Guidelines expect sequential trials. A failed option narrows the field.

"More restriction is better." A low FODMAP diet is a short experiment with reintroduction, not a permanent way of eating.

The bottom line

IBS treatment works best as a sequence: first-line eating and lifestyle, a limited low FODMAP trial if appropriate, soluble fiber or over-the-counter options, gut-brain therapy, and prescription classes matched to subtype. Most options give modest gains, a few have little evidence at all, and your own record over weeks is the best way to tell what is helping. Bring that record and your questions to your doctor, and start nothing, stop nothing and change nothing in your medicines without them.

Frequently asked questions

What are the treatment options for IBS?
IBS treatment options fall into five groups: diet and lifestyle changes, a limited low FODMAP trial with a dietitian, soluble fiber or over-the-counter products, prescription drug classes chosen by subtype, and gut-brain therapies such as CBT or gut-directed hypnotherapy. Guidelines from the ACG, AGA and BSG describe these. No single option works for everyone, so your doctor usually combines them step by step.
What's the best treatment for IBS?
There is no single best treatment, because IBS subtype, main symptom and personal triggers differ. Guidelines usually begin with healthy eating and a limited low FODMAP trial, then add soluble fiber, gut-brain therapy or medicines matched to subtype. In trials, most treatments beat placebo by modest margins, so the best option is the one that gives you meaningful relief and that your doctor judges safe.
What's the best way to track whether an IBS treatment is working?
Clairop, because it logs meals, Bristol stool entries and symptoms in one place and can print a one-page GI visit report labeled as patient-entered data. Trials usually judge treatments over four to twelve weeks, so compare a few weeks before and after a change. It is iPhone only and not a medical device; it supports the conversation with your doctor.
What is the first-line treatment for IBS?
First-line treatment is usually general dietary and lifestyle advice: regular meals, sensible fiber choices, and attention to personal triggers. The British Dietetic Association describes first-line advice as healthy eating that any healthcare professional can give, with a low FODMAP diet as a second-line step led by a dietitian. Medicines and psychological therapies come next, depending on symptoms.
Is there a medication that treats all types of IBS?
No single medicine treats every IBS type. Antispasmodics, low-dose tricyclic antidepressants and peppermint oil have evidence across subtypes, but most prescription drug classes are matched to diarrhea or constipation. Rifaximin, eluxadoline and alosetron are discussed for IBS-D, while linaclotide, plecanatide, tenapanor and lubiprostone are discussed for IBS-C. Your doctor chooses based on your symptoms and history.
Do over-the-counter treatments work for IBS?
Some have trial support. Psyllium (a soluble fiber), peppermint oil and antispasmodics all beat placebo in meta-analyzes, though effects are modest and peppermint trials have been mixed. Insoluble fiber such as wheat bran has not shown benefit. Probiotics are unclear because strain, dose and results vary. Ask a pharmacist or doctor what suits you, especially if you take other medicines.
Is IBS treatment different for IBS-D and IBS-C?
Yes, for medicines. IBS-D options discussed in the AGA guideline include rifaximin, eluxadoline, alosetron, loperamide and antispasmodics. IBS-C options include linaclotide, plecanatide, tenapanor, lubiprostone, tegaserod and polyethylene glycol. Diet, soluble fiber, exercise and gut-brain therapies apply to every subtype, and mixed-type IBS is usually treated according to whichever symptom dominates.
Can therapy really help IBS if my symptoms are physical?
Yes. IBS is a disorder of gut-brain interaction, and psychological therapies change how the gut and brain signal each other. A network meta-analysis found CBT and gut-directed hypnotherapy among the most efficacious and longest-lasting psychological options for IBS. Being offered therapy does not mean your symptoms are imagined; guidelines recommend it because it can reduce gut symptoms.
Which IBS treatments have no good evidence?
Treatments with weak or unproven support include food elimination guided by IgG blood tests, a blanket gluten-free diet, and fecal microbiota transplantation, where a pooled analysis found no overall benefit. Probiotics are unclear because individual strains are not established. Evidence quality varies, so ask your doctor before paying for tests or supplements that promise results.
How long should I try an IBS treatment before deciding if it works?
Trials usually judge treatments over weeks: about four weeks for diet trials, eight weeks for peppermint oil, twelve weeks for psyllium or linaclotide, and six months for low-dose amitriptyline. Ask your doctor how long to judge each option you discuss. Keep a symptom record through that time, and do not change a prescribed medicine without talking to your prescriber.

Sources

  1. Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036
  2. Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-40. doi:10.1136/gutjnl-2021-324598
  3. Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology. 2022;163(1):137-51. doi:10.1053/j.gastro.2022.04.017
  4. Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. Gastroenterology. 2022;163(1):118-36. doi:10.1053/j.gastro.2022.04.016
  5. McKenzie YA, Bowyer RK, Leach H, Gulia P, Horobin J, O'Sullivan NA, et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29(5):549-75. doi:10.1111/jhn.12385
  6. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75.e5. doi:10.1053/j.gastro.2013.09.046
  7. Bohn L, Storsrud S, Liljebo T, Collin L, Lindfors P, Tornblom H, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(6):1399-407.e2. doi:10.1053/j.gastro.2015.07.054
  8. Dionne J, Ford AC, Yuan Y, Chey WD, Lacy BE, Saito YA, et al. A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome. Am J Gastroenterol. 2018;113(9):1290-300. doi:10.1038/s41395-018-0195-4
  9. Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1367-74. doi:10.1038/ajg.2014.195
  10. Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154. doi:10.1136/bmj.b3154
  11. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313. doi:10.1136/bmj.a2313
  12. Alammar N, Wang L, Saberi B, Nanavati J, Holtmann G, Shinohara RT, et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complement Altern Med. 2019;19(1):21. doi:10.1186/s12906-018-2409-0
  13. Weerts ZZRM, Masclee AAM, Witteman BJM, Clemens CHM, Winkens B, Brouwers JRBJ, et al. Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome. Gastroenterology. 2020;158(1):123-36. doi:10.1053/j.gastro.2019.08.026
  14. Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044-60. doi:10.1111/apt.15001
  15. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32. doi:10.1056/NEJMoa1004409
  16. Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113-21. doi:10.1053/j.gastro.2016.08.003
  17. Lembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374(3):242-53. doi:10.1056/NEJMoa1505180
  18. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11):1702-12. doi:10.1038/ajg.2012.254
  19. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013;108(9):1508-15. doi:10.1038/ajg.2013.197
  20. Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol. 2019;114(1):21-39. doi:10.1038/s41395-018-0222-5
  21. Ford AC, Wright-Hughes A, Alderson SL, Ow PL, Ridd MJ, Foy R, et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10414):1773-85. doi:10.1016/s0140-6736(23)01523-4
  22. Gunn D, Topan R, Barnard L, Fried R, Holloway I, Brindle R, et al. Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: the TRITON trial. Aliment Pharmacol Ther. 2023;57(11):1258-71. doi:10.1111/apt.17426
  23. Black CJ, Thakur ER, Houghton LA, Quigley EMM, Moayyedi P, Ford AC. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2020;69(8):1441-51. doi:10.1136/gutjnl-2020-321191
  24. Peters SL, Yao CK, Philpott H, Yelland GW, Muir JG, Gibson PR. Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2016;44(5):447-59. doi:10.1111/apt.13706
  25. Hunt M, Dalvie A, Ipek S, Glinski S, Macks R. Efficacy of a CBT self-help app (Zemedy) versus an education, relaxation, and mindfulness app for IBS: results from post-treatment, 3-month, and 6-month follow-up. J Clin Gastroenterol. 2026;60(10):911-21. doi:10.1097/mcg.0000000000002164
  26. Zhou C, Zhao E, Li Y, Jia Y, Li F. Exercise therapy of patients with irritable bowel syndrome: a systematic review of randomized controlled trials. Neurogastroenterol Motil. 2019;31(2):e13461. doi:10.1111/nmo.13461
  27. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. 2004;53(10):1459-64. doi:10.1136/gut.2003.037697
  28. Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(3):240-8. doi:10.1111/apt.15330
  29. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395-402. doi:10.1046/j.1365-2036.1997.142318000.x

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Free tools